The SH-SY5Y cell line is a human neuroblastoma cell line derived from a metastatic bone marrow biopsy obtained from a 4-year-old female patient with neuroblastoma 1. First established in the 1970s, this cell line has become one of the most widely used in vitro models for studying dopaminergic neuronal function and neurodegeneration, particularly in Parkinson's disease research 2.
The cell line exhibits a hybrid phenotype consisting of both neuroblastic and epithelial characteristics. When properly differentiated, SH-SY5Y cells express neuronal markers including tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine biosynthesis, demonstrate dopamine uptake capacity, and generate action potentials 3. These properties make it a valuable model for investigating the molecular mechanisms underlying dopaminergic neuron degeneration.
SH-SY5Y is a subclone of the original SK-N-SH cell line, which was derived from a metastatic bone marrow lesion of a neuroblastoma patient. The SH-SY5Y subclone was selected for its neuronal properties and has been extensively characterized. Key features include:
The cell line has been deposited in major cell banks including ATCC (CRL-2266) and DSMZ (ACC 209), ensuring accessibility for researchers worldwide.
Differentiation of SH-SY5Y cells into a more neuronal phenotype is essential for modeling neurodegeneration. Multiple protocols have been developed, each yielding cells with distinct characteristics:
The most widely used approach involves treatment with 10μM all-trans retinoic acid (RA) for 5-7 days 3. RA activates nuclear receptors (RAR/RXR) that drive transcription of neuronal genes including:
For enhanced dopaminergic differentiation, sequential treatment with retinoic acid followed by brain-derived neurotrophic factor (BDNF) is recommended 4:
This protocol produces cells with:
Other differentiation agents include:
SH-SY5Y cells serve as a critical model for investigating multiple aspects of PD pathogenesis:
The alpha-synuclein protein is central to PD pathogenesis. SH-SY5Y cells have been engineered to overexpress wild-type and mutant α-syn (A30P, A53T) to model:
LRRK2 (Leucine-Rich Repeat Kinase 2) mutations are a common genetic cause of familial PD. SH-SY5Y cells expressing mutant LRRK2 (G2019S, R1441C/G) demonstrate:
The mitochondrial complex I dysfunction observed in PD patient brains is replicated in SH-SY5Y using:
These models reveal:
PINK1 and Parkin pathway dysfunction leads to impaired mitophagy in PD. SH-SY5Y cells have been used to demonstrate:
GBA1 mutations increase PD risk substantially. SH-SY5Y models of glucocerebrosidase deficiency show:
Although primarily a PD model, SH-SY5Y cells also serve AD research:
Amyloid-beta (Aβ) peptide exposure models AD neurodegeneration:
Tau hyperphosphorylation is replicated using:
SH-SY5Y cells enable high-throughput screening for:
The development of efficient CRISPR systems in SH-SY5Y enables:
Multiple stable lines are available:
For transient gene silencing:
As a tumor-derived line, SH-SY5Y cells differ from primary neurons:
For certain applications, alternative models may be superior:
| Model | Advantages | Limitations |
|---|---|---|
| iPSC-derived neurons | Patient-specific, true neuronal | Cost, time, variability |
| Primary neurons | Native phenotype | Limited availability, short lifespan |
| Midbrain organoids | 3D architecture, multiple cell types | Complexity, variability |
| LUHMES cells | Immortalized, floor plate origin | Less characterized |
Medium: DMEM/F12 + 10% FBS + 1% NEAA
Passage: 1:3 to 1:6 every 3-4 days
Split: 70-80% confluency
Mycoplasma: Regular testing recommended
# Day 0: Plate cells at 2×10⁴ cells/cm²
# Day 1-7: Add 10μM retinoic acid
# Day 8-14: Add 50ng/mL BDNF
# Day 14+: Assess differentiation markers
For toxin models:
Emerging applications include: